 Onconova Therapeutics, Inc. NASDAQ:ONTX shares are trading higher after the company reported preliminary data from a Phase 12 a trial of rigosertib plus immune checkpoint inhibitor nivolumab, which are being presented at the 3rd Annual RAS Targeted Drug Development Summit. Onconova Therapeutics is currently up 32.3 to a price of 6.48. 